CMA consults on bipolar drug commitments
Essential Pharma has promised to continue supplying a bipolar drug to UK patients, likely addressing the UK competition authority’s concerns that it abused its dominance by planning to withdraw the medication from the national market.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10